Search

Your search keyword '"Cellini, C."' showing total 275 results
Start Over Author "Cellini, C."
275 results on '"Cellini, C."'

4. A RANDOMIZED TRIAL OF OBSERVATION VERSUS RADIOTHERAPY IN PRIMARY MEDIASTINAL B‐CELL LYMPHOMA PATIENTS WITH COMPLETE METABOLIC RESPONSE AFTER STANDARD IMMUNOCHEMOTHERAPY.

Author

Davies, A. J., Zucca, E., Ceriani, L., Kryachok, I., Ciccone, G., Botto, B., Balzarotti, M., Tucci, A., Rusconi, C., Usai, S. V., Pennese, E., Arcaini, L., Dabrowska‐Iwanicka, A., Ferreri, A. J. M., Merli, F., Zhao, W., Hodgson, D., Rigacci, L., Cellini, C., and Stelitano, C.

Subjects
LYMPHOMAS
Abstract

The IELSG37 (NCT01599559) randomized trial was planned with a non-inferiority design to test whether RT can be omitted in PMBCL patients who achieve a complete metabolic response (CMR) after immunochemotherapy. Mediastinal radiotherapy (RT) may consolidate responses to dose-intensive immunochemotherapy; however, it increases the risk of second malignancies and coronary or valvular heart disease. B Introduction: b Primary mediastinal B-cell lymphoma (PMBCL) has a poor prognosis if remission is not rapidly achieved, or the disease recurs. [Extracted from the article]

Published
2023
Full Text
View/download PDF

5. Italian cystic fibrosis registry (ICFR): Report 2017-2018

Author

Campagna, G., Amato, A., Majo, F., Ferrari, G., Quattrucci, S., Padoan, R., Floridia, G., Salvatore, D., Carnovale, V., Fornaro, G. P., Taruscio, D., Salvatore, M., Angiolillo, A., Baldo, E., Battistini, F., Bernardi, M. A., Bertasi, S., Bignamini, E., Bisogno, A., Braggion, C., Caloiero, M., Cannata, L., Carnicella, A., Cellini, C., Ciciretti, M. A., Cimino, G., Cipolli, M., Cirilli, N., Collura, M., Colombo, C., Sabatino, M. D., Donati, V., Fabrizi, B., Ficili, F., Francalanci, M., Iansa, P., Laezza, C., Leonardi, S., Lucanto, M. C., Lucidi, V., Macchiaroli, A. M., Manca, A., Maschio, M., Mascotto, D., Mencarini, V., Messore, B., Minicucci, L., Moretti, P., Negri, A., Pantano, S., Palladino, N., Pintani, E., Pisano, G., Pisi, G., Pizzamiglio, G., Quattromano, E., Raia, V., Redemagni, A., Ros, M., Rotolo, N., Rottigni, S., Scarlata, A., Spaggiari, C., Taccetti, G., Vassanelli, C., and Vitullo, P.

Subjects
Adult, Male, CF referral centre, Registry, Adolescent, Cystic Fibrosis, [delta]F508, Cystic Fibrosis Transmembrane Conductance Regulator, FEV, BMI, Young Adult, CF support centre, Italy, Cystic fibrosis, Child, Female, Humans, Registries, Lung Transplantation
Published
2021

6. Bortezomib-dexamethasone as maintenance therapy or early retreatment at biochemical relapse versus observation in relapsed/refractory multiple myeloma patients: a randomized phase II study

Author

Mina, R. (Roberto), Belotti, A. (Angelo), Petrucci, M. (Maria), Zambello, R. (Renato), Capra, A. (Andrea), Di Lullo, G. (Giacomo), Ronconi, S. (Sonia), Pescosta, N. (Norbert), Grasso, M. (Mariella), Monaco, F. (Federico), Cellini, C. (Claudia), Gobbi, M. (Marco), Ballanti, S. (Stelvio), de Fabritiis, P. (Paolo), Mosca-Siez, M.L. (Maria Letizia), Marchetti, M. (Monia), Liberati, A.M., Offidani, M. (Massimo), Giuliani, N. (Nicola), Ria, R. (Roberto), Musto, P. (Pellegrino), Romano, A. (Alessandra), Sonneveld, P. (Pieter), Boccadoro, M. (Mario), Larocca, A. (Alessandra), Mina, R. (Roberto), Belotti, A. (Angelo), Petrucci, M. (Maria), Zambello, R. (Renato), Capra, A. (Andrea), Di Lullo, G. (Giacomo), Ronconi, S. (Sonia), Pescosta, N. (Norbert), Grasso, M. (Mariella), Monaco, F. (Federico), Cellini, C. (Claudia), Gobbi, M. (Marco), Ballanti, S. (Stelvio), de Fabritiis, P. (Paolo), Mosca-Siez, M.L. (Maria Letizia), Marchetti, M. (Monia), Liberati, A.M., Offidani, M. (Massimo), Giuliani, N. (Nicola), Ria, R. (Roberto), Musto, P. (Pellegrino), Romano, A. (Alessandra), Sonneveld, P. (Pieter), Boccadoro, M. (Mario), and Larocca, A. (Alessandra)

Published
2020
Full Text
View/download PDF

7. Bortezomib-dexamethasone as maintenance therapy or early retreatment at biochemical relapse versus observation in relapsed/refractory multiple myeloma patients: a randomized phase II study

Author

Mina, R, Belotti, A, Petrucci, MT, Zambello, R, Capra, A, Di Lullo, G, Ronconi, S, Pescosta, N, Grasso, M, Monaco, F, Cellini, C, Gobbi, M, Ballanti, S, de Fabritiis, P, Mosca-Siez, ML, Marchetti, M, Liberati, AM, Offidani, M, Giuliani, N, Ria, R, Musto, P, Romano, A, Sonneveld, Pieter, Boccadoro, M, Larocca, A, Mina, R, Belotti, A, Petrucci, MT, Zambello, R, Capra, A, Di Lullo, G, Ronconi, S, Pescosta, N, Grasso, M, Monaco, F, Cellini, C, Gobbi, M, Ballanti, S, de Fabritiis, P, Mosca-Siez, ML, Marchetti, M, Liberati, AM, Offidani, M, Giuliani, N, Ria, R, Musto, P, Romano, A, Sonneveld, Pieter, Boccadoro, M, and Larocca, A

Published
2020

14. Effect of Recombinant Zoster Vaccine on Incidence of Herpes Zoster After Autologous Stem Cell Transplantation A Randomized Clinical Trial

Author

Bastidas, A, de la Serna, J, El Idrissi, M, Oostvogels, L, Quittet, P, Lopez-Jimenez, J, Vural, F, Pohlreich, D, Zuckerman, T, Issa, NC, Gaidano, G, Lee, JJ, Abhyankar, S, Solano, C, de Oteyza, JP, Satlin, MJ, Schwartz, S, Campins, M, Rocci, A, Llamas, CV, Lee, DG, Tan, SM, Johnston, AM, Grigg, A, Boeckh, MJ, Campora, L, Lopez-Fauqued, M, Heineman, TC, Stadtmauer, EA, Sullivan, KM, Alonso, AA, Anagnostopoulos, A, Andreadis, C, Angelopoulou, M, Anttila, VJ, Aoun, M, Barista, I, Berkahn, L, Bloor, AJC, Broady, R, Brossart, P, Buadi, FK, Bulabois, CE, Cantin, G, Cellini, C, Chandrasekar, PH, Chauncey, T, Cuneo, A, Dadwal, SS, Dickinson, M, Eom, H, Sanfeliu, AE, Coll, CF, Flomenberg, PR, Gonzalez-Rodriguez, AP, Gottlieb, DJ, Grisariu, S, Guenther, A, Gutman, J, Hahn, U, Heinz, WJ, Heras, I, Ikeda, T, Jarque, I, Karthaus, M, Kerre, T, Kiani, A, Klein, AK, Kofla, G, Kryuchkova, IV, Kuo, CY, Kuruvilla, J, Kuvshinov, A, Kwak, JY, Lee, JH, Lepretre, S, Lie, AKW, Lucchesi, A, Maertens, J, Marijt, EWA, Munoz, CM, Michieli, M, Milliken, ST, Milpied, N, Coll, JM, Mossad, SB, Murphy, J, Matilla, MBN, Novak, J, Olney, HJ, Navarrete, RO, Cascon, MJP, Peniket, A, Penka, G, Piatkowska-Jakubas, B, Zarzuela, MP, Quiel, D, Rowley, SD, Sabry, W, Salmi, TM, Selleslag, DLD, Shea, TC, Silling, G, Sinisalo, UM, Sohn, SK, Staib, P, Szer, J, Theunissen, K, Topcuoglu, P, Tyurina, NG, Uvarov, M, Wahid, FSA, San Segundo, LY, Yegin, ZA, Yeh, SP, Yip, SF, Yoon, SS, Young, JAH, Zachee, P, Zaja, F, and ZOE-HSCT Study Grp Collaborators

Abstract

IMPORTANCE Herpes zoster, a frequent complication following autologous hematopoietic stem cell transplantation (HSCT), is associated with significant morbidity. A nonlive adjuvanted recombinant zoster vaccine has been developed to prevent posttransplantation zoster. OBJECTIVE To assess the efficacy and adverse event profile of the recombinant zoster vaccine in immunocompromised autologous HSCT recipients. DESIGN, SETTING, AND PARTICIPANTS Phase 3, randomized, observer-blinded study conducted in 167 centers in 28 countries between July 13, 2012, and February 1, 2017, among 1846 patients aged 18 years or older who had undergone recent autologous HSCT. INTERVENTIONS Participants were randomized to receive 2 doses of either recombinant zoster vaccine (n=922) or placebo (n=924) administered into the deltoid muscle; the first dose was given 50 to 70 days after transplantation and the second dose 1 to 2 months thereafter. MAIN OUTCOMES AND MEASURES The primary end point was occurrence of confirmed herpes zoster cases. RESULTS Among 1846 autologous HSCT recipients (mean age, 55 years; 688 [37%] women) who received 1 vaccine or placebo dose, 1735 (94%) received a second dose and 1366 (74%) completed the study. During the 21-month median follow-up, at least 1 herpes zoster episode was confirmed in 49 vaccine and 135 placebo recipients (incidence, 30 and 94 per 1000 person-years, respectively), an incidence rate ratio (IRR) of 0.32 (95% CI, 0.22-0.44; P

Published
2019

15. Stopping and damage parameters for Monte Carlo simulation of MeV implants in crystalline Si

Author

Lulli, G., Albertazzi, E., Bianconi, M., Nipoti, R., Cervera, M., Carnera, A., and Cellini, C.

Subjects
Ions -- Models, Monte Carlo method -- Usage, Silicon crystals -- Research, Physics
Abstract

Semiempirical models were developed for MeV ion electronic energy loss and damage formation. The B. P and As ions were implanted at room temperature in silicon. The models were examined by comparing measurements with Monte Carlo impurity and damage depth distribution simulations. Results reveal a systematic underestimate of simulated damage distribution peak depth position.

Published
1997

20. PF579 TUMOR CIRCULATING PLASMA CELLS DETECTED BY FLOW CYTOMETRIC SINGLE PLATFORM METHOD ARE RELATED TO NEGATIVE PATIENTS‘ CHARACTERISTICS IN MULTIPLE MYELOMA

Author

Muccio, V.E., primary, Gilestro, M., additional, Saraci, E., additional, Spada, S., additional, Capra, A., additional, Costa, A., additional, Ruggeri, M., additional, Galieni, P., additional, Curci, P., additional, Pescosta, N., additional, De Rosa, L., additional, Pavone, V., additional, Ronconi, S., additional, Cellini, C., additional, Vincelli, I.D., additional, Musolino, C., additional, Cafro, A.M., additional, Piro, E., additional, Caltagirone, S., additional, Oddolo, D., additional, Mussatto, C., additional, Gay, F., additional, Boccadoro, M., additional, and Omedè, P., additional

Published
2019
Full Text
View/download PDF

24. OBINUTUZUMAB-MINICHOP FOR THE TREATMENT OF ELDERLY UNFIT PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA. A STUDY OF THE FONDAZIONE ITALIANA LINFOMI

Author

Merli, F., primary, Luminari, S., additional, Salvi, F., additional, Cavallo, F., additional, Gini, G., additional, Musuraca, G., additional, Gaidano, G., additional, Cellini, C., additional, Merli, M., additional, Ferrari, A., additional, Molinari, A., additional, Liberati, A.M., additional, Conconi, A., additional, Matteucci, P., additional, Pozzi, S., additional, Musso, M., additional, Mammi, C., additional, Monaco, F., additional, Ferrero, S., additional, and Tucci, A., additional

Published
2017
Full Text
View/download PDF

25. Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma

Author

Cavo, M, Pantani, L, Petrucci, M, Patriarca, F, Zamagni, E, Donnarumma, D, Crippa, C, Boccadoro, M, Perrone, G, Falcone, A, Nozzoli, C, Zambello, R, Masini, L, Furlan, A, Brioli, A, Derudas, D, Ballanti, S, Dessanti, M, De Stefano, V, Carella, A, Marcatti, M, Nozza, A, Ferrara, F, Callea, V, Califano, C, Pezzi, A, Baraldi, A, Grasso, M, Musto, P, Palumbo, A, Tosi, P, Motta, M, Rizzi, S, Fanin, R, Buttignol, S, Foà, R, Levi, A, Calabrese, E, Rambaldi, A, Galli, M, Rossi, G, Ferrari, S, Bringhen, S, Leoni, P, Offidani, M, Polloni, C, Corradini, P, Montefusco, V, Torelli, G, Narni, F, Fioritoni, G, Spadano, A, Cortelazzo, S, Pescosta, N, Billio, A, Lambertenghi Deliliers, G, Baldini, L, Onida, F, Annaloro, C, La Nasa, G, Ledda, A, Zaccaria, A, Cellini, C, De Fabritiis, P, Caravita, T, Siniscalchi, A, Cascavilla, N, Bosi, A, Semenzato, G, Gugliotta, L, Merli, F, Gherlinzoni, F, Angelucci, E, Martelli, M, Petti, M, Pisani, F, Leone, G, Rossi, E, Za, T, Fianchi, L, Catania, G, Spriano, M, Ciceri, F, Peccatori, J, Girlanda, S, Santoro, A, Castagna, L, Palmieri, S, Nobile, F, D'Arco, A, Levis, A, Primon, V, Tamiazzo, S, Guardigni, L, Pasini, S, Gallamini, A, Pietrantuono, G, Martorelli, M, Fattori, P, Pasquini, E, Galieni, P, Ruggieri, M, Morandi, S, Tajana, M, Amadori, D, Ronconi, S, Cangini, D, Ceccolini, M, Gobbi, M, Ballerini, F, Pane, F, Catalano, L, Cangialosi, C, Vallisa, D, Lazzaro, A, Paladini, G, De Sabbata, G, Mozzana, R, Ciambelli, F, Pinotti, G, Rodeghiero, F, Elice, F, Cantore, N, Volpe, S, Pavone, V, Mele, A, Pogliani, E, Rossini, F, Liberati, A, Majolino, I, De Rosa, L, Amadori, S, Rizzo, M, Lauria, F, Gozzetti, A, Aglietta, M, Capaldi, A, Quarta, G, Mele, G, Storti, S, Fraticelli, V, Morabito, F, Gentile, C, Capalbo, S, Gianni, A, Magni, M, Mettivier, V, Nunziata, G, Rizzoli, V, Giuliani, N, Crugnola, M, Bernasconi, C, Fregoni, V, Visani, G, Olivieri, A, Pizzuti, M, La Verde, G, Moscetti, A, Avvisati, G, Tirindelli, M, Longinotti, M, Podda, L, Gallo, E, Pregno, P, Dammacco, F, Perosa, F, Russo, D, Roccaro, A, Bacigalupo, A, Dominietto, A, Musolino, C, Quartarone, E, Tosi P, Motta MR, Rizzi S, Fanin R, Buttignol S, Foà R, Levi A, Calabrese E, Rambaldi A, Galli M, Rossi G, Ferrari S, Bringhen S, Leoni P, Offidani M, Polloni C, Corradini P, Montefusco V, Torelli G, Narni F, Fioritoni G, Spadano A, Cortelazzo S, Pescosta N, Billio A, Lambertenghi Deliliers G, Baldini L, Onida F, Annaloro C, La Nasa G, Ledda A, Zaccaria A, Cellini C, De Fabritiis P, Caravita T, Siniscalchi A, Cascavilla N, Bosi A, Semenzato G, Gugliotta L, Merli F, Gherlinzoni F, Angelucci E, Martelli M, Petti MC, Pisani F, Leone G, Rossi E, Za T, Fianchi L, Catania G, Spriano M, Ciceri F, Peccatori J, Girlanda S, Santoro A, Castagna L, Palmieri S, Nobile F, D'Arco AM, Levis A, Primon V, Tamiazzo S, Guardigni L, Pasini S, Gallamini A, Pietrantuono G, Martorelli MC, Fattori P, Pasquini E, Galieni P, Ruggieri M, Morandi S, Tajana M, Amadori D, Ronconi S, Cangini D, Ceccolini M, Gobbi M, Ballerini F, Pane F, Catalano L, Cangialosi C, Vallisa D, Lazzaro A, Paladini G, De Sabbata G, Mozzana R, Ciambelli F, Pinotti G, Rodeghiero F, Elice F, Cantore N, Volpe S, Pavone V, Mele A, POGLIANI, ENRICO MARIA, Rossini F, Liberati A, Majolino I, De Rosa L, Amadori S, Rizzo M, Lauria F, Gozzetti A, Aglietta M, Capaldi A, Quarta G, Mele G, Storti S, Fraticelli V, Morabito F, Gentile C, Capalbo S, Gianni A, Magni M, Mettivier V, Nunziata G, Rizzoli V, Giuliani N, Crugnola M, Bernasconi C, Fregoni V, Visani G, Olivieri A, Pizzuti M, La Verde G, Moscetti A, Avvisati G, Tirindelli M, Longinotti M, Podda L, Gallo E, Pregno P, Dammacco F, Perosa F, Russo D, Roccaro A, Bacigalupo A, Dominietto A, Musolino C, Quartarone E., Cavo, M, Pantani, L, Petrucci, M, Patriarca, F, Zamagni, E, Donnarumma, D, Crippa, C, Boccadoro, M, Perrone, G, Falcone, A, Nozzoli, C, Zambello, R, Masini, L, Furlan, A, Brioli, A, Derudas, D, Ballanti, S, Dessanti, M, De Stefano, V, Carella, A, Marcatti, M, Nozza, A, Ferrara, F, Callea, V, Califano, C, Pezzi, A, Baraldi, A, Grasso, M, Musto, P, Palumbo, A, Tosi, P, Motta, M, Rizzi, S, Fanin, R, Buttignol, S, Foà, R, Levi, A, Calabrese, E, Rambaldi, A, Galli, M, Rossi, G, Ferrari, S, Bringhen, S, Leoni, P, Offidani, M, Polloni, C, Corradini, P, Montefusco, V, Torelli, G, Narni, F, Fioritoni, G, Spadano, A, Cortelazzo, S, Pescosta, N, Billio, A, Lambertenghi Deliliers, G, Baldini, L, Onida, F, Annaloro, C, La Nasa, G, Ledda, A, Zaccaria, A, Cellini, C, De Fabritiis, P, Caravita, T, Siniscalchi, A, Cascavilla, N, Bosi, A, Semenzato, G, Gugliotta, L, Merli, F, Gherlinzoni, F, Angelucci, E, Martelli, M, Petti, M, Pisani, F, Leone, G, Rossi, E, Za, T, Fianchi, L, Catania, G, Spriano, M, Ciceri, F, Peccatori, J, Girlanda, S, Santoro, A, Castagna, L, Palmieri, S, Nobile, F, D'Arco, A, Levis, A, Primon, V, Tamiazzo, S, Guardigni, L, Pasini, S, Gallamini, A, Pietrantuono, G, Martorelli, M, Fattori, P, Pasquini, E, Galieni, P, Ruggieri, M, Morandi, S, Tajana, M, Amadori, D, Ronconi, S, Cangini, D, Ceccolini, M, Gobbi, M, Ballerini, F, Pane, F, Catalano, L, Cangialosi, C, Vallisa, D, Lazzaro, A, Paladini, G, De Sabbata, G, Mozzana, R, Ciambelli, F, Pinotti, G, Rodeghiero, F, Elice, F, Cantore, N, Volpe, S, Pavone, V, Mele, A, Pogliani, E, Rossini, F, Liberati, A, Majolino, I, De Rosa, L, Amadori, S, Rizzo, M, Lauria, F, Gozzetti, A, Aglietta, M, Capaldi, A, Quarta, G, Mele, G, Storti, S, Fraticelli, V, Morabito, F, Gentile, C, Capalbo, S, Gianni, A, Magni, M, Mettivier, V, Nunziata, G, Rizzoli, V, Giuliani, N, Crugnola, M, Bernasconi, C, Fregoni, V, Visani, G, Olivieri, A, Pizzuti, M, La Verde, G, Moscetti, A, Avvisati, G, Tirindelli, M, Longinotti, M, Podda, L, Gallo, E, Pregno, P, Dammacco, F, Perosa, F, Russo, D, Roccaro, A, Bacigalupo, A, Dominietto, A, Musolino, C, Quartarone, E, Tosi P, Motta MR, Rizzi S, Fanin R, Buttignol S, Foà R, Levi A, Calabrese E, Rambaldi A, Galli M, Rossi G, Ferrari S, Bringhen S, Leoni P, Offidani M, Polloni C, Corradini P, Montefusco V, Torelli G, Narni F, Fioritoni G, Spadano A, Cortelazzo S, Pescosta N, Billio A, Lambertenghi Deliliers G, Baldini L, Onida F, Annaloro C, La Nasa G, Ledda A, Zaccaria A, Cellini C, De Fabritiis P, Caravita T, Siniscalchi A, Cascavilla N, Bosi A, Semenzato G, Gugliotta L, Merli F, Gherlinzoni F, Angelucci E, Martelli M, Petti MC, Pisani F, Leone G, Rossi E, Za T, Fianchi L, Catania G, Spriano M, Ciceri F, Peccatori J, Girlanda S, Santoro A, Castagna L, Palmieri S, Nobile F, D'Arco AM, Levis A, Primon V, Tamiazzo S, Guardigni L, Pasini S, Gallamini A, Pietrantuono G, Martorelli MC, Fattori P, Pasquini E, Galieni P, Ruggieri M, Morandi S, Tajana M, Amadori D, Ronconi S, Cangini D, Ceccolini M, Gobbi M, Ballerini F, Pane F, Catalano L, Cangialosi C, Vallisa D, Lazzaro A, Paladini G, De Sabbata G, Mozzana R, Ciambelli F, Pinotti G, Rodeghiero F, Elice F, Cantore N, Volpe S, Pavone V, Mele A, POGLIANI, ENRICO MARIA, Rossini F, Liberati A, Majolino I, De Rosa L, Amadori S, Rizzo M, Lauria F, Gozzetti A, Aglietta M, Capaldi A, Quarta G, Mele G, Storti S, Fraticelli V, Morabito F, Gentile C, Capalbo S, Gianni A, Magni M, Mettivier V, Nunziata G, Rizzoli V, Giuliani N, Crugnola M, Bernasconi C, Fregoni V, Visani G, Olivieri A, Pizzuti M, La Verde G, Moscetti A, Avvisati G, Tirindelli M, Longinotti M, Podda L, Gallo E, Pregno P, Dammacco F, Perosa F, Russo D, Roccaro A, Bacigalupo A, Dominietto A, Musolino C, and Quartarone E.

Abstract

In a randomized, phase 3 study, superior complete/near-complete response (CR/nCR) rates and extended progression-free survival were demonstrated with bortezomib-thalidomide-dexamethasone (VTD) versus thalidomide-dexamethasone (TD) as induction therapy before, and consolidation after, double autologous stem cell transplantation for newly diagnosed myeloma patients (intention-to-treat analysis; VTD, n = 236; TD, n = 238). This per-protocol analysis (VTD, n = 160; TD, n = 161) specifically assessed the efficacy and safety of consolidation with VTD or TD. Before starting consolidation, CR/nCR rates were not significantly different in the VTD (63.1%) and TD arms (54.7%). After consolidation, CR (60.6% vs 46.6%) and CR/nCR (73.1% vs 60.9%) rates were significantly higher for VTD-treated versus TD-treated patients. VTD consolidation significantly increased CR and CR/nCR rates, but TD did not (McNemar test). With a median follow-up of 30.4 months from start of consolidation, 3-year progression-free survival was significantly longer for the VTD group (60% vs 48% for TD). Grade 2 or 3 peripheral neuropathy (8.1% vs 2.4%) was more frequent with VTD (grade 3, 0.6%) versus TD consolidation. The superior efficacy of VTD versus TD as induction was retained despite readministration as consolidation therapy after double autologous transplantation. VTD consolidation therapy significantly contributed to improved clinical outcomes observed for patients randomly assigned to the VTD arm of the study. The study is registered at www.clinicaltrials.gov as #NCT01134484.

Published
2012

26. Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy following autologous hematopoietic stem-cell transplantation in patients with newly diagnosed multiple myeloma

Author

Cavo, Michele, Pantani, Lucia, Petrucci, Maria Teresa, Patriarca, Francesca, Zamagni, Elena, Donnarumma, Daniela, Crippa, Claudia, Boccadoro, Mario, Perrone, Giulia, Falcone, Antonietta, Nozzoli, Chiara, Zambello, Renato, Masini, Luciano, Furlan, Anna, Brioli, Annamaria, Derudas, Daniele, Ballanti, Stelvio, Dessanti, Maria Laura, De Stefano, Valerio, Carella, Angelo Michele, Marcatti, Magda, Nozza, Andrea, Ferrara, Felicetto, Callea, Vincenzo, Califano, Catello, Pezzi, Annalisa, Baraldi, Anna, Grasso, Mariella, Musto, Pellegrino, Palumbo, Antonio COLLABORATORI: Tosi, P, Motta, Mr, Rizzi, S, Fanin, R, Buttignol, S, Foà, R, Levi, A, Calabrese, E, Rambaldi, A, Galli, M, Rossi, G, Ferrari, S, Bringhen, S, Leoni, P, Offidani, M, Polloni, C, Corradini, P, Montefusco, V, Torelli, G, Narni, Franco, Fioritoni, G, Spadano, A, Cortelazzo, S, Pescosta, N, Billio, A, Lambertenghi Deliliers, G, Baldini, L, Onida, F, Annaloro, C, La Nasa, G, Ledda, A, Zaccaria, A, Cellini, C, De Fabritiis, P, Caravita, T, Siniscalchi, A, Cascavilla, N, Bosi, A, Semenzato, G, Gugliotta, L, Merli, F, Gherlinzoni, F, Angelucci, E, Martelli, M, Petti, Mc, Pisani, F, Leone, G, Rossi, E, Za, T, Fianchi, L, Catania, G, Spriano, M, Ciceri, F, Peccatori, J, Girlanda, S, Santoro, A, Castagna, L, Palmieri, S, Nobile, F, D'Arco, Am, Levis, A, Primon, V, Tamiazzo, S, Guardigni, L, Pasini, S, Gallamini, A, Pietrantuono, G, Martorelli, Mc, Fattori, P, Pasquini, E, Galieni, P, Ruggieri, M, Morandi, S, Tajana, M, Amadori, D, Ronconi, S, Cangini, D, Ceccolini, M, Gobbi, M, Ballerini, F, Pane, F, Catalano, L, Cangialosi, C, Vallisa, D, Lazzaro, A, Paladini, G, De Sabbata, G, Mozzana, R, Ciambelli, F, Pinotti, G, Rodeghiero, F, Elice, F, Cantore, N, Volpe, S, Pavone, V, Mele, A, Pogliani, E, Rossini, F, Liberati, A, Majolino, I, De Rosa, L, Amadori, S, Rizzo, M, Lauria, F, Gozzetti, A, Aglietta, M, Capaldi, A, Quarta, G, Mele, G, Storti, S, Fraticelli, V, Morabito, F, Gentile, C, Capalbo, S, Gianni, A, Magni, M, Mettivier, V, Nunziata, G, Rizzoli, V, Giuliani, N, Crugnola, M, Bernasconi, C, Fregoni, V, Visani, G, Olivieri, A, Pizzuti, M, La Verde, G, Moscetti, A, Avvisati, G, Tirindelli, M, Longinotti, M, Podda, L, Gallo, E, Pregno, P, Dammacco, F, Perosa, F, Russo, D, Roccaro, A, Bacigalupo, A, Dominietto, A, Musolino, C, Quartarone, E., Cavo M, Pantani L, Petrucci MT, Patriarca F, Zamagni E, Donnarumma D, Crippa C, Boccadoro M, Perrone G, Falcone A, Nozzoli C, Zambello R, Masini L, Furlan A, Brioli A, Derudas D, Ballanti S, Dessanti ML, De Stefano V, Carella AM, Marcatti M, Nozza A, Ferrara F, Callea V, Califano C, Pezzi A, Baraldi A, Grasso M, Musto P, Palumbo A., Cavo, Michele, Pantani, Lucia, Petrucci, Maria Teresa, Patriarca, Francesca, Zamagni, Elena, Donnarumma, Daniela, Crippa, Claudia, Boccadoro, Mario, Perrone, Giulia, Falcone, Antonietta, Nozzoli, Chiara, Zambello, Renato, Masini, Luciano, Furlan, Anna, Brioli, Annamaria, Derudas, Daniele, Ballanti, Stelvio, Dessanti, Maria Laura, De Stefano, Valerio, Carella, Angelo Michele, Marcatti, Magda, Nozza, Andrea, Ferrara, Felicetto, Callea, Vincenzo, Califano, Catello, Pezzi, Annalisa, Baraldi, Anna, Grasso, Mariella, Musto, Pellegrino, Palumbo, Antonio, Cavo, M, Pantani, L, Petrucci, M, Patriarca, F, Zamagni, E, Donnarumma, D, Crippa, C, Boccadoro, M, Perrone, G, Falcone, A, Nozzoli, C, Zambello, R, Masini, L, Furlan, A, Brioli, A, Derudas, D, Ballanti, S, Dessanti, M, De Stefano, V, Carella, A, Marcatti, M, Nozza, A, Ferrara, F, Callea, V, Califano, C, Pezzi, A, Baraldi, A, Grasso, M, Musto, P, Palumbo, A, Tosi, P, Motta, M, Rizzi, S, Fanin, R, Buttignol, S, Foà, R, Levi, A, Calabrese, E, Rambaldi, A, Galli, M, Rossi, G, Ferrari, S, Bringhen, S, Leoni, P, Offidani, M, Polloni, C, Corradini, P, Montefusco, V, Torelli, G, Narni, F, Fioritoni, G, Spadano, A, Cortelazzo, S, Pescosta, N, Billio, A, Lambertenghi Deliliers, G, Baldini, L, Onida, F, Annaloro, C, La Nasa, G, Ledda, A, Zaccaria, A, Cellini, C, De Fabritiis, P, Caravita, T, Siniscalchi, A, Cascavilla, N, Bosi, A, Semenzato, G, Gugliotta, L, Merli, F, Gherlinzoni, F, Angelucci, E, Martelli, M, Petti, M, Pisani, F, Leone, G, Rossi, E, Za, T, Fianchi, L, Catania, G, Spriano, M, Ciceri, F, Peccatori, J, Girlanda, S, Santoro, A, Castagna, L, Palmieri, S, Nobile, F, D'Arco, A, Levis, A, Primon, V, Tamiazzo, S, Guardigni, L, Pasini, S, Gallamini, A, Pietrantuono, G, Martorelli, M, Fattori, P, Pasquini, E, Galieni, P, Ruggieri, M, Morandi, S, Tajana, M, Amadori, D, Ronconi, S, Cangini, D, Ceccolini, M, Gobbi, M, Ballerini, F, Pane, F, Catalano, L, Cangialosi, C, Vallisa, D, Lazzaro, A, Paladini, G, De Sabbata, G, Mozzana, R, Ciambelli, F, Pinotti, G, Rodeghiero, F, Elice, F, Cantore, N, Volpe, S, Pavone, V, Mele, A, Pogliani, E, Rossini, F, Liberati, A, Majolino, I, De Rosa, L, Amadori, S, Rizzo, M, Lauria, F, Gozzetti, A, Aglietta, M, Capaldi, A, Quarta, G, Mele, G, Storti, S, Fraticelli, V, Morabito, F, Gentile, C, Capalbo, S, Gianni, A, Magni, M, Mettivier, V, Nunziata, G, Rizzoli, V, Giuliani, N, Crugnola, M, Bernasconi, C, Fregoni, V, Visani, G, Olivieri, A, Pizzuti, M, La Verde, G, Moscetti, A, Avvisati, G, Tirindelli, M, Longinotti, M, Podda, L, Gallo, E, Pregno, P, Dammacco, F, Perosa, F, Russo, D, Roccaro, A, Bacigalupo, A, Dominietto, A, Musolino, C, and Quartarone, E

Subjects
Male, Boronic Acid, medicine.medical_treatment, PLUS DEXAMETHASONE, Phases of clinical research, Kaplan-Meier Estimate, Hematopoietic stem cell transplantation, Biochemistry, Antineoplastic Agent, Bortezomib-thalidomide-dexamethasone, Bortezomib, Immunosuppressive Agent, Autologous stem-cell transplantation, MULTIPLE MYELOMA, Antineoplastic Combined Chemotherapy Protocols, thalidomide-dexamethasone, Multiple myeloma, RANDOMIZED PHASE-3, LENALIDOMIDE, STEM CELL TRANSPLANTATION, Hematopoietic Stem Cell Transplantation, PHASE-III TRIAL, Hematology, Middle Aged, CHEMOTHERAPY, Prognosis, Boronic Acids, Combined Modality Therapy, Thalidomide, Transplantation, Autologou, Pyrazines, HIGH-DOSE MELPHALAN, INDUCTION TREATMENT, Female, Autologous, Immunosuppressive Agents, Pyrazine, Human, medicine.drug, MAINTENANCE THERAPY, medicine.medical_specialty, DOXORUBICIN, Antineoplastic Agents, Hormonal, Prognosi, Immunology, Urology, Antineoplastic Agents, dexamethasone, Transplantation, Autologous, Disease-Free Survival, Dexamethasone, Humans, Multiple Myeloma, Cell Biology, medicine, Autologous transplantation, METAANALYSIS, Transplantation, Antineoplastic Combined Chemotherapy Protocol, Hormonal, business.industry, medicine.disease, Surgery, business, Settore MED/15 - Malattie del Sangue
Abstract

In a randomized, phase 3 study, superior complete/near-complete response (CR/nCR) rates and extended progression-free survival were demonstrated with bortezomib-thalidomide-dexamethasone (VTD) versus thalidomide-dexamethasone (TD) as induction therapy before, and consolidation after, double autologous stem cell transplantation for newly diagnosed myeloma patients (intention-to-treat analysis; VTD, n = 236; TD, n = 238). This per-protocol analysis (VTD, n = 160; TD, n = 161) specifically assessed the efficacy and safety of consolidation with VTD or TD. Before starting consolidation, CR/nCR rates were not significantly different in the VTD (63.1%) and TD arms (54.7%). After consolidation, CR (60.6% vs 46.6%) and CR/nCR (73.1% vs 60.9%) rates were significantly higher for VTD-treated versus TD-treated patients. VTD consolidation significantly increased CR and CR/nCR rates, but TD did not (McNemar test). With a median follow-up of 30.4 months from start of consolidation, 3-year progression-free survival was significantly longer for the VTD group (60% vs 48% for TD). Grade 2 or 3 peripheral neuropathy (8.1% vs 2.4%) was more frequent with VTD (grade 3, 0.6%) versus TD consolidation. The superior efficacy of VTD versus TD as induction was retained despite readministration as consolidation therapy after double autologous transplantation. VTD consolidation therapy significantly contributed to improved clinical outcomes observed for patients randomly assigned to the VTD arm of the study. The study is registered at www.clinicaltrials.gov as #NCT01134484.

Published
2012

27. The buzz-lag effect

Author

Cellini, C, Scocchia, L, Drewing, K, SCOCCHIA, LISA, Drewing, K., Cellini, C, Scocchia, L, Drewing, K, SCOCCHIA, LISA, and Drewing, K.

Abstract

In the flash-lag illusion, a brief visual flash and a moving object presented at the same location appear to be offset with the flash trailing the moving object. A considerable amount of studies investigated the visual flash-lag effect, and flash-lag-like effects have also been observed in audition, and cross-modally between vision and audition. In the present study, we investigate whether a similar effect can also be observed when using only haptic stimuli. A fast vibration (or buzz, lasting less than 20 ms) was applied to the moving finger of the observers and employed as a “haptic flash.” Participants performed a two-alternative forced-choice (2AFC) task where they had to judge whether the moving finger was located to the right or to the left of the stationary finger at the time of the buzz. We used two different movement velocities (Slow and Fast conditions). We found that the moving finger was systematically misperceived to be ahead of the stationary finger when the two were physically aligned. This result can be interpreted as a purely haptic analogue of the flash-lag effect, which we refer to as “buzz-lag effect.” The buzz-lag effect can be well accounted for by the temporal-sampling explanation of flash-lag-like effects.

Published
2016

28. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study

Author

Cavo, M, Tacchetti, P, Patriarca, F, Petrucci, Mt, Pantani, L, Galli, M, Di Raimondo, F, Crippa, C, Zamagni, E, Palumbo, Antonio, Offidani, M, Corradini, P, Narni, F, Spadano, A, Pescosta, N, Deliliers, Gl, Ledda, A, Cellini, C, Caravita, T, Tosi, P, Baccarani, M, GIMEMA Italian Myeloma Network, Aglietta, Massimo, Cavo M, Tacchetti P, Patriarca F, Petrucci MT, Pantani L, Galli M, Di Raimondo F, Crippa C, Zamagni E, Palumbo A, Offidani M, Corradini P, Narni F, Spadano A, Pescosta N, Deliliers GL, Ledda A, Cellini C, Caravita T, Tosi P, and Baccarani M

Subjects
Male, stem-cell, Kaplan-Meier Estimate, autologous, Dexamethasone, Bortezomib, Autologous stem-cell transplantation, Antineoplastic Combined Chemotherapy Protocols, Adjuvant, Multiple myeloma, Antibacterial agent, Medicine (all), Remission Induction, Hematopoietic Stem Cell Transplantation, thalidomide, transplantation, myeloma, General Medicine, Middle Aged, Boronic Acids, Neoadjuvant Therapy, Thalidomide, Treatment Outcome, Italy, Chemotherapy, Adjuvant, Adult, Aged, Disease-Free Survival, Drug Administration Schedule, Female, Humans, Multiple Myeloma, Pyrazines, Reoperation, Transplantation, Autologous, Autologous, medicine.drug, medicine.medical_specialty, Internal medicine, medicine, Chemotherapy, Transplantation, Intention-to-treat analysis, business.industry, medicine.disease, Surgery, business, dexamethasone, multiple myeloma
Abstract

Thalidomide plus dexamethasone (TD) is a standard induction therapy for myeloma. We aimed to assess the efficacy and safety of addition of bortezomib to TD (VTD) versus TD alone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma.Patients (aged 18-65 years) with previously untreated symptomatic myeloma were enrolled from 73 sites in Italy between May, 2006, and April, 2008, and data collection continued until June 30, 2010. Patients were randomly allocated (1:1 ratio) by a web-based system to receive three 21-day cycles of thalidomide (100 mg daily for the first 14 days and 200 mg daily thereafter) plus dexamethasone (40 mg daily on 8 of the first 12 days, but not consecutively; total of 320 mg per cycle), either alone or with bortezomib (1·3 mg/m(2) on days 1, 4, 8, and 11). The randomisation sequence was computer generated by the study coordinating team and was stratified by disease stage. After double autologous stem-cell transplantation, patients received two 35-day cycles of their assigned drug regimen, VTD or TD, as consolidation therapy. The primary endpoint was the rate of complete or near complete response to induction therapy. Analysis was by intention to treat. Patients and treating physicians were not masked to treatment allocation. This study is still underway but is not recruiting participants, and is registered with ClinicalTrials.gov, number NCT01134484, and with EudraCT, number 2005-003723-39.480 patients were enrolled and randomly assigned to receive VTD (n=241 patients) or TD (n=239). Six patients withdrew consent before start of treatment, and 236 on VTD and 238 on TD were included in the intention-to-treat analysis. After induction therapy, complete or near complete response was achieved in 73 patients (31%, 95% CI 25·0-36·8) receiving VTD, and 27 (11%, 7·3-15·4) on TD (p0·0001). Grade 3 or 4 adverse events were recorded in a significantly higher number of patients on VTD (n=132, 56%) than in those on TD (n=79, 33%; p0·0001), with a higher occurrence of peripheral neuropathy in patients on VTD (n=23, 10%) than in those on TD (n=5, 2%; p=0·0004). Resolution or improvement of severe peripheral neuropathy was recorded in 18 of 23 patients on VTD, and in three of five patients on TD.VTD induction therapy before double autologous stem-cell transplantation significantly improves rate of complete or near complete response, and represents a new standard of care for patients with multiple myeloma who are eligible for transplant.Seràgnoli Institute of Haematology at the University of Bologna, Bologna, Italy.

Published
2010

29. BENDAMUSTINE, BORTEZOMIB AND DEXAMETHASONE (BVD) EXERT A SUBSTANTIAL ACTIVITY WITH A MANAGEABLE TOXICITY IN PATIENTS WITH RELAPSED-REFRACTORY MULTIPLE MYELOMA

Author

Offidani, M., Corvatta, L., Maracci, L., Liberati, Am, Ballanti, S., Attoli co, I., Caraffa, P., Alesiani, F., Caravita di Toritto, T., Gentili, S., Tosi, P., Brunori, M., Derudas, D., Ledda, A., Gozzetti, A., Cellini, C., Malerba, L., Mele, A., Felici, S., Galimberti, Sara, Mondello, P., Pulini, S., Coppetelli, U., Fraticelli, P., and Leoni, P.

Published
2014

31. Efficacy and safety of 3 lenalidomide–based combinations in elderly newly diagnosed multiple myeloma patients: results from the phase 3 community based EMN01 trial

Author

Gay, F, Bringhen, S, Offidani, M, Liberati, Am, Cellini, C, Magarotto, V, Benevolo, G, Aitoro, G, Patriarca, F, Omede, P, Conticello, C, Montefusco, V, Rossi, D, Palladino, C, Pour, L, Allegra, Alessandro, Pietrantuono, G, Falcone, Ap, Rocci, A, Zambello, R, Ledda, A, Gentili, S, Musto, P, Boccadoro, M, Hajek, R, and Palumbo, A.

Subjects
Multiple myeloma, Lenalidomide, EMN01, EMN01, Multiple myeloma, Lenalidomide
Published
2013

32. How do patients with aggressive non-Hodgkin's lymphoma treated with third-generation regimens (MACOP-B and F-MACHOP) fare in the long-term?

Author

Zinzani PL, Martelli M, Magagnoli M, ZAJA, Francesco, Storti S, Pavone E, Lauta VM, De Renzo A, Gobbi M, Bocchia M, Ronconi F, Scaramucci L, Gherlinzoni F, Palombi F, Bendandi M, Stefoni V, Anticoli Borza P, Cellini C, Mandelli F, Tura S., Zinzani, Pl, Martelli, M, Magagnoli, M, Zaja, Francesco, Storti, S, Pavone, E, Lauta, Vm, De Renzo, A, Gobbi, M, Bocchia, M, Ronconi, F, Scaramucci, L, Gherlinzoni, F, Palombi, F, Bendandi, M, Stefoni, V, Anticoli Borza, P, Cellini, C, Mandelli, F, and Tura, S.

Subjects
Adult, Male, Salvage Therapy, Adolescent, Lymphoma, Non-Hodgkin, Cytarabine, Leucovorin, Middle Aged, Disease-Free Survival, Bleomycin, Methotrexate, Treatment Outcome, Doxorubicin, Vincristine, Antineoplastic Combined Chemotherapy Protocols, Humans, Prednisone, Female, Fluorouracil, Cyclophosphamide, Retrospective Studies
Abstract

BACKGROUND AND OBJECTIVE: To examine the long-term clinical course and prognostic factors of patients with advanced aggressive non-Hodgkin's lymphoma (NHL) treated with third-generation regimens as front-line chemotherapy. DESIGN AND METHODS: A total of 348 patients aged

Published
1999

33. Early Mortality in Elderly Patients With Newly Diagnosed Multiple Myeloma Treated With Novel Agents

Author

Larocca, A., primary, Bringhen, S., additional, Petrucci, M.T., additional, Offidani, M., additional, Benevolo, G., additional, Galli, M., additional, Patriarca, F., additional, Ballanti, S., additional, Palladino, C., additional, Pescosta, N., additional, Grasso, M., additional, Evangelista, A., additional, Spada, S., additional, Pezzati, S., additional, Pulini, S., additional, Bernardini, A., additional, Rota-Scalabrini, D., additional, Morabito, F., additional, Tosi, P., additional, Oliva, S., additional, Baldini, M., additional, Marasca, R., additional, Finsinger, P., additional, Cellini, C., additional, Ria, R., additional, Aitoro, G., additional, Hajek, R., additional, Boccadoro, M., additional, and Palumbo, A., additional

Published
2015
Full Text
View/download PDF

34. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction before, and consolidation after, double autologous stem cell transplantation in newly diagnosed multiple myeloma: a randomized phase 3 study

Author

Cavo, M, Tacchetti, P, Patriarca, Francesca, Petrucci, Mt, Pantani, L, Galli, M, Di Raimondo, F, Crippa, C, Zamagni, E, Palumbo, A, Offidani, M, Corradini, P, Narni, F, Spadano, A, Pescosta, N, Lambertenghi Deliliers, G, Ledda, A, Cellini, C, Caravita, T, Tosi, P, Baccarani, M, and GIMEMA Italian Myeloma Network

Published
2010

35. Five-year follow-up of children with perinatal HIV-1 infection receiving early highly active antiretroviral therapy

Author

Author:, Chiappini, Galli, E, Tovo, L, Gabiano, Pa, Lisi, C, Bernardi, C, Vigano, S, Guarino, A, Giaquinto, A, Esposito, C, Badolato, S, R, Bari, Di, Rosso, C, Genovese, R, Masi, O, Mazza, M, A, Martino, De, Italian Register for HIV Infection Other Partecipants: Osimani, M., Cordiali, P, Mattia, De, Manzinonna, D, M, Ruggeri, C, Masi, M, Miniaci, M, Specchia, A, Ciccia, F, Lanari, M, Baldi, M, Battisti, F, Bertulli, L, Dessì, C, Pintor, C, Dedoni, C, Fenu, M, Cavallini, Ml, Anastasio, R, Magnolia, E, Sticca, Mg, Pomero, M, Bezzi, G, Fiumana, T, Bonsignori, E, F, Gaudio, De, Gervaso, M, Cecchi, P, Viscoli, Mt, Cosso, C, Timitilli, D, Stronati, A, Plebani, M, Semino, A, Tei, M, Giacomet, F, Pivetti, V, Salvini, V, Zuccotti, F, Giovannini, Gv, Ferraris, M, Liprieri, G, Moretti, R, Cellini, C, Cano, M, Paolucci, Mc, Bruzzese, P, Giannattasio, E, Tarallo, A, Tancredi, L, Pennazzato, F, Rampon, M, O, Dalle, Nogare, Sanfilippo, Er, Romano, A, Saitta, M, Dodi, I, Bandello, M, Maccabruni, A, Felici, L, Consolini, Rita, Chiappini E., Galli L., Tovo PA., Gabiano C., Lisi C., Bernardi S., Viganò A., Guarino A., Giaquinto C., Esposito S., Badolato R., Di Bari C., Rosso R., Genovese O., Masi M., Mazza A., de Martino M., Specchia F., Molesini M., Chiappini, E., Galli, L., Tovo, P. -A., Gabiano, C., Lisi, C., Bernardi, S., Vigano, A., Guarino, A., Giaquinto, C., Esposito, S., Badolato, R., Di Bari, C., Rosso, R., Genovese, O., Masi, M., Mazza, A., and De Martino, M.

Subjects
medicine.medical_specialty, Pediatrics, Anti-HIV Agents, HIV Infections, Follow-Up Studie, lcsh:Infectious and parasitic diseases, Pharmacotherapy, Medical microbiology, Interquartile range, Antiretroviral Therapy, Highly Active, medicine, Humans, HIV Infection, lcsh:RC109-216, Child, Pregnancy, business.industry, Anti-HIV Agent, Infant, Viral Load, medicine.disease, Antiretroviral therapy, hiv children, CD4 Lymphocyte Count, Regimen, Infectious Diseases, Italy, Child, Preschool, Tropical medicine, Immunology, HIV-1, RNA, Viral, business, Viral load, Research Article, Follow-Up Studies, Human
Abstract

Background Early highly active antiretroviral therapy (HAART), started within the first months of age, has been proven to be the optimal strategy to prevent immunological and clinical deterioration in perinatally HIV-infected children. Nevertheless, data about long-term follow-up of early treated children are lacking. Methods We report data from 40 perinatally HIV-infected-children receiving early HAART, with a median follow-up period of 5.96 years (interquartile range [IQR]:4.21–7.62). Children were enrolled at birth in the Italian Register for HIV Infection in Children. Comparison with 91 infected children born in the same period, followed-up from birth, and receiving deferred treatment was also provided. Results Nineteen children (47.5%) were still receiving their first HAART regimen at last follow-up. In the remaining children the first regimen was discontinued, after a median period of 3.77 years (IQR: 1.71–5.71) because of viral failure (8 cases), liver toxicity (1 case), structured therapy interruption (3 cases), or simplification/switch to a PI-sparing regimen (9 cases). Thirty-nine (97.5%) children showed CD4+ T-lymphocyte values>25%, and undetectable viral load was reached in 31 (77.5%) children at last visit. Early treated children displayed significantly lower viral load than not-early treated children, until 6 years of age, and higher median CD4+ T-lymphocyte percentages until 4 years of age. Twenty-seven (29.7%) not-early treated vs. 0/40 early treated children were in clinical category C at last follow-up (P < 0.0001). Conclusion Our findings suggest that clinical, virologic and immunological advantages from early-HAART are long-lasting. Recommendations indicating the long-term management of early treated children are needed.

Published
2009

36. Superior complete response rate and progression-free survival after autologous stem-cell transplantation (ASCT) incorporating velcade-thalidomide-dexamethasone (VTD)compared to thalidomide-dexametha-sone (TD) in newly diagnosed multiple myelona

Author

Cavo, M, Pantani, L, Patriarca, F, Petrucci, M. T., Tacchetti, P, Galli, L, DI RAIMONDO, Francesco, Crippa, C, Bringhen, S, Montefusco, V, Narni, F, Offidani, M, Spadano, T, Olivero, B, Pescosta, N, Caravita, T, Cellini, C, Ledda, A, Falcone, A, Agostini, P, Cavraro, M, Masini, L, Nozzoli, C, Ballanti, S, Derudas, D, DE STEFANO, V, Pisani, F, Califano, C, Callea, V, Catania, G, Nozza, A, Palmieri, S, Peccatori, J, Baraldi, A, Fattori, Pp, Pasini, S, Musto, P, Grasso, M, Ballerini, F, Cangialosi, C, Catalano, L, Morandi, S, Ronconi, S, and Baccarani, M.

Published
2009

37. Final analysis of the multicenter phase II 'Bologna 2002' study incorporating thalidomide-dexamethasone (thal-dex) into up-front double autologous stem-cell transplantation (ASCT) for multiple myeloma

Author

Zamagni, E, Testoni, N, Terragna, C, Tachetti, P, Nicci, C, Renzulli, M, Tosi, P, Fiacchini, M, Patriarca, F, DI RAIMONDO, Francesco, Catalano, L, Casulli, A. F., Volpe, S, Masini, L, Ledda, A, Brioli, A, Falcioni, S, Gozzetti, A, Califano, C, Pallotti, M. C., Cellini, C, Carubbelli, A, Petrucci, A, Stefani, P. M., Pantani, L, Ceccolini, M, Perrone, G, Baccarini, M, and Cavo, M.

Published
2009

38. INCORPORATION OF THALIDOMIDE INTO UP-FRONT DOUBLE AUTOLOGOUS TRANSPLANTATION FOR MULTIPLE MYELOMA: PROGNOSTIC RELEVANCE OF BASELINE CYTOGENETIC ABNORMALITIES

Author

Tacchetti, P, Testoni, N, Terragna, C, Nicci, C, Renzulli, M, Zamagni, E, Tosi, P, Fiacchini, M, Patriarca, F, DI RAIMONDO, Francesco, Perrone, G, Catalano, L, Casulli, Af, Ceccolini, M, Volpe, S, Masini, L, Ledda, A, Brioli, A, Falcioni, S, Gozzetti, A, Califano, C, Pallotti, Mc, Cellini, C, Carubelli, A, Stefani, Pm, Baccarani, M, and Cavo, M.

Published
2007

43. Il ruolo dell’arteria radiale nella rivascolarizzazione miocardica

Author

Manasse E, Alessandrini F, Cellini C, Canosa C, De Filippo C, Martinelli L, Schiavello R, Possati G.F., DE BONIS , MICHELE, Manasse, E, Alessandrini, F, Cellini, C, Canosa, C, De Filippo, C, DE BONIS, Michele, Martinelli, L, Schiavello, R, and Possati, G. F.

Published
1995

Catalog

Books, media, physical & digital resources
See catalog results